Vyome develops treatments for rare and immune inflammatory diseases and sells antifungal products in India. HIND reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 3 | Chardan Capital | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in HIND in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HIND is in one of them and how their past HIND trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered HIND in an article yet. Here's the latest on the wider market.
About Vyome Holdings
Vyome is a clinical stage specialty pharmaceutical company developing treatments for immune inflammatory and rare diseases. Its lead program is a topical gel for symptoms of malignant fungating wounds in advanced cancer. Its other development programs target uveitis, an eye condition, and moderate to severe acne, and none of its candidates is approved for sale. The company also sells dandruff lotion and shampoo, both antifungal products, in India through a licensing partner, Sun Pharma. It is based in San Clemente, California, with operations in Massachusetts, New Jersey and New Delhi, India.
- Headquarters
- San Clemente, CA